00:38 , Jan 6, 2018 |  BioCentury  |  Finance

Burgeoning bellwethers

  The miserable performance of large cap biotechs last quarter is likely to be a boon for small- and mid-cap players this year, in more ways than one. Buysiders spent most of 2017 focusing to...
01:41 , May 5, 2017 |  BC Week In Review  |  Clinical News

Kiadis submits MAA for HSCT adjunct ATIR101

Kiadis Pharma N.V. (Euronext:KDS) submitted an MAA to EMA for ATIR101 as an adjunct therapy to hematopoietic stem cell transplantation (HSCT) for hematological cancers. The company expects a decision in 2H18 and hopes to launch...
20:15 , Feb 16, 2017 |  BC Week In Review  |  Clinical News

ATIR101: Ph III CR-AIR-009 started

Kiadis began the open-label, international Phase III CR-AIR-009 trial to compare T cell-depleted HSCT followed by IV ATIR101 vs. T cell replete HSCT followed by high-dose cyclophosphamide in about 195 patients. In 2012, Hospira Inc....
01:38 , Dec 30, 2016 |  BC Week In Review  |  Clinical News

ATIR101: Ph II amended

Kiadis will drop the second infusion of ATIR101 given 70-74 days after HSCT from a haploidentical donor in the open-label, international Phase II CIR-AIR-008 trial based on an independent DSMB recommendation. The trial will continue...
08:00 , Dec 21, 2015 |  BC Week In Review  |  Clinical News

ATIR: Phase II data

Data from 19 evaluable patients with a hematologic malignancy in the open-label, international Phase II CR-AIR-007 trial showed that a single IV infusion of 2x10 6 CD3+ cells/kg ATIR101 following an HSCT from a haploidentical...
08:00 , Nov 9, 2015 |  BC Week In Review  |  Clinical News

ATIR: Phase II started

Kiadis began the open-label, international Phase II CR-AIR-008 trial in 15 patients with a hematologic malignancy to evaluate 2 infusions of ATIR101 given 28-32 days and 70-74 days after HSCT from a haploidentical donor. In...
07:00 , Aug 17, 2015 |  BC Week In Review  |  Clinical News

ATIR: Completed Phase II enrollment

Kiadis completed enrollment of 23 patients with a hematologic malignancy following HSCT in the open-label, international Phase II CR-AIR-007 trial to evaluate a single infusion of ATIR101. ATIR101 has Orphan Drug designation in the U.S....
00:47 , Jul 2, 2015 |  BC Extra  |  Financial News

Kiadis raises EUR 32.7M in IPO

Kiadis Pharma B.V. (Euronext:KDS) raised EUR 32.7 million ($36.2 million) through the sale of 2.6 million shares at EUR 12.50 in an IPO underwritten by Kempen; KBC Securities; and Peel Hunt. The IPO price values...
07:00 , Jun 8, 2015 |  BioCentury  |  Finance

Staying local, thinking global

Kiadis Pharma B.V. hopes to double up the local hero effect with its planned IPO on both Euronext Amsterdam and Euronext Brussels while still attracting about half of its new investors from the U.S. The...
07:00 , May 25, 2015 |  BC Week In Review  |  Clinical News

ATIR regulatory update

EMA classified Kiadis’ ATIR as an advanced therapy medicinal product (ATMP). ATIR is in Phase II testing to reduce transplant-related mortality following hematopoietic stem cell transplant (HSCT) in patients with a hematologic malignancy. The therapy...